miR-106b has been shown to participate in activation of the TGF-β/Smad signaling pathway by inhibiting Smad7 protein expression to intensify the epithelial mesenchymal transition (EMT) in breast cancer cells [13]. Here, SMAD7 is linked to breast cancer.